Cann Group cites positive press coverage as possible reason for share price surge by Martin Lane September 30, 2024September 30, 2024 Cann Group has told the Australian Securities Exchange (ASX) a recent surge in its share price […]
Company news: Cann Group; Helius Therapeutics/Novachem; Elixinol/HFA by Martin Lane September 4, 2024September 5, 2024
Cann Group confirms Jenni Pilcher as MD and CEO after drawing up ‘well-defined strategy’ by Steve Jones July 18, 2024July 18, 2024
Cann Group secures additional funding, reissues half-year results by Steve Jones May 9, 2024July 16, 2024
Cann Group takes steps to resume ASX trading as Q3 revenues tumble and cash flow worsens by Steve Jones April 30, 2024April 30, 2024
